Literature DB >> 10886347

Activation of spinal cannabinoid 1 receptors inhibits C-fibre driven hyperexcitable neuronal responses and increases [35S]GTPgammaS binding in the dorsal horn of the spinal cord of noninflamed and inflamed rats.

L J Drew1, J Harris, P J Millns, D A Kendall, V Chapman.   

Abstract

The analgesic potential of cannabinoid (CB) receptor agonists is of clinical interest. Improved understanding of the mechanisms of action of cannabinoids at sites involved in the modulation of acute and sustained inflammatory nociceptive transmission, such as the spinal cord, is essential. In vivo electrophysiology was used to compare the effect of the synthetic CB agonist, HU210, on acute transcutaneous electrical-evoked responses of dorsal horn neurons of noninflamed anaesthetized rats and anaesthetized rats with a peripheral carrageenin inflammation. CB receptor G-protein coupling in lumbar spinal cord sections of noninflamed and carrageenin-inflamed rats was studied with in vitro autoradiography of guanylyl 5'-[gamma-[35S]thio]triphosphate ([35S]GTPgammaS) binding. Spinal HU210 significantly inhibited the C-fibre-mediated late (300-800 ms) postdischarge response of dorsal horn neurons of noninflamed and carrageenin-inflamed rats; the CB1 receptor antagonist SR141716A blocked the effect of HU210. HU210 had limited effects on A-fibre-evoked dorsal horn neuronal responses of both groups of rats. HU210 significantly increased [35S]GTPgammaS binding in the dorsal horn of the spinal cord of both groups of rats compared with basal [35S]GTPgammaS binding; SR141716A blocked these effects. The predominant effect of spinal HU210, via CB1 receptor activation, was on the C-fibre driven postdischarge responses, a measure of neuronal hyperexcitability following repetitive C-fibre stimulation. Sustained, but not enhanced, antinociceptive effects of HU210 following carrageenin inflammation are reported; CB receptor G-protein coupling was not altered by inflammation. These results strengthen the body of evidence suggesting CB agonists may be an important novel analgesic approach for the treatment of sustained pain states.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10886347     DOI: 10.1046/j.1460-9568.2000.00101.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  22 in total

1.  Reduction of bone cancer pain by CB1 activation and TRPV1 inhibition.

Authors:  Tomoyuki Kawamata; Yukitoshi Niiyama; Jun Yamamoto; Shingo Furuse
Journal:  J Anesth       Date:  2010-04-07       Impact factor: 2.078

2.  The antinociceptive effects of intraplantar injections of 2-arachidonoyl glycerol are mediated by cannabinoid CB2 receptors.

Authors:  J Guindon; J Desroches; P Beaulieu
Journal:  Br J Pharmacol       Date:  2006-12-18       Impact factor: 8.739

3.  Intrathecal cannabinoid-1 receptor agonist prevents referred hyperalgesia in acute acrolein-induced cystitis in rats.

Authors:  Marsha Ritter Jones; Zun-Yi Wang; Dale E Bjorling
Journal:  Am J Clin Exp Urol       Date:  2015-04-25

4.  Role of cannabinoid receptor 1 and the peroxisome proliferator-activated receptor α in mediating anti-nociceptive effects of synthetic cannabinoids and a cannabinoid-like compound.

Authors:  Mohammad Alsalem; Mansour Haddad; Sara A Aldossary; Heba Kalbouneh; Ahmad Altarifi; Sahar M Jaffal; Manal A Abbas; Nour Aldaoud; Khalid El-Salem
Journal:  Inflammopharmacology       Date:  2019-04-03       Impact factor: 4.473

Review 5.  Physical activity and the endocannabinoid system: an overview.

Authors:  Mirko Tantimonaco; Roberta Ceci; Stefania Sabatini; Maria Valeria Catani; Antonello Rossi; Valeria Gasperi; Mauro Maccarrone
Journal:  Cell Mol Life Sci       Date:  2014-02-14       Impact factor: 9.261

6.  Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms.

Authors:  Leon Chang; Lin Luo; James A Palmer; Steven Sutton; Sandy J Wilson; Ann J Barbier; James Guy Breitenbucher; Sandra R Chaplan; Michael Webb
Journal:  Br J Pharmacol       Date:  2006-05       Impact factor: 8.739

7.  Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats.

Authors:  E J Rahn; A Makriyannis; A G Hohmann
Journal:  Br J Pharmacol       Date:  2007-06-18       Impact factor: 8.739

8.  Contrasting effects of WIN 55212-2 on motility of the rat bladder and uterus.

Authors:  Natalia Dmitrieva; Karen J Berkley
Journal:  J Neurosci       Date:  2002-08-15       Impact factor: 6.167

9.  Cannabinoid-induced presynaptic inhibition at the primary afferent trigeminal synapse of juvenile rat brainstem slices.

Authors:  Ying-Ching Liang; Chiung-Chun Huang; Kuei-Sen Hsu; Tomoyuki Takahashi
Journal:  J Physiol       Date:  2003-12-12       Impact factor: 5.182

10.  Molecular architecture of endocannabinoid signaling at nociceptive synapses mediating analgesia.

Authors:  Rita Nyilas; Laura C Gregg; Ken Mackie; Masahiko Watanabe; Andreas Zimmer; Andrea G Hohmann; István Katona
Journal:  Eur J Neurosci       Date:  2009-05-09       Impact factor: 3.386

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.